<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892525</url>
  </required_header>
  <id_info>
    <org_study_id>ITSELF</org_study_id>
    <nct_id>NCT03892525</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma</brief_title>
  <official_title>Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic
      anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with
      anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or
      relapsed B cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV</measure>
    <time_frame>21 days (1 cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall metabolic response (BOMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse event (SAE)</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selicrelumab</intervention_name>
    <description>escalated dose in intratumoral injection, every 3 weeks, for 3 cycles</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200mg IV every 3 week until progression or relapse for maximum 1 year</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 and older

          2. Histologically confirmed diagnosis of recurrent or refractory B-non-Hodgkin's lymphoma
             (NHL)

          3. At least one injectable lesion:

             i) at least one nodal lesion amenable to intratumoral injection and biopsy (including
             deep lesions accessible by interventional radiology either under US or CT-scan
             guidance). The first injected lesion should be of at least 2 x 1.5 cm in diameter. The
             subsequent lesions to be injected should be ≥1.5 cm in diameter. Extra nodal lesions
             will not be considered as injectable lesion.

             ii) OR One cutaneous lesion of at least ≥ 1 cm in diameter. Other extra nodal lesion
             will not be considered as injectable lesion.

          4. Patient must have a 18-F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) avid
             lymphoma that can be followed by positron emission tomography (PET).

          5. Bi-dimensionally measurable disease defined by at least one measurable lesion
             according to Lugano criteria, with at least 1cm in its shortest diameter and 1.5cm in
             largest diameter (different from the lesion that will be injected)

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1

          7. Signed written informed consent

          8. Life expectancy ≥ 3 months

          9. Patients must have recovered to ≤ grade 1 from all toxicities related to prior
             treatments excluding alopecia.

         10. Patients must be naïve from immunotherapy with anti-PD1/PDL1 or agonistic anti-CD40
             therapy

         11. Adequate laboratory parameters:

               -  Hb ≥ 9 g/dl

               -  absolute neutrophil count (ANC) ≥ 1000/μL

               -  Platelet count ≥ 50,000/μL

               -  Total bilirubin &lt; 2.5 times the institutional upper limit of normal (ULN) (3.5 x
                  ULN if liver involvement)

               -  Hepatic enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT)
                  ) ≤ 2.5 x ULN (5 x ULN if liver involvement)

               -  Serum creatinine &lt; 2.0 x ULN or creatinine clearance &gt;50 mL/mn

               -  International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) &gt;1.5 ×
                  ULN

         12. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test within 72 hours prior to the start of study drug administration.

         13. Persons of reproductive potential must agree to use an adequate method of
             contraception throughout treatment and for at least 6 months after study drug is
             stopped.

             *Highly effective method includes: combined (estrogen and progestogen containing)
             hormonal contraception associated with inhibition of ovulation 1 (oral/ intravaginal/
             transdermal); progestogen-only hormonal contraception associated with inhibition of
             ovulation 1 (oral/injectable/implantable); intrauterine device (IUD); intrauterine
             hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner;
             sexual abstinence

         14. Patient covered by any social security system (France)

         15. Patient who understands and speaks one of the country official language

        Exclusion Criteria:

          1. Immature B cell malignancies (B-acute lymphoblastic leukemia (ALL), Burkitt lymphoma)
             and T-cell lymphomas

          2. History of severe allergic anaphylactic reactions to chimeric, human or humanized
             antibodies, or fusion proteins or known hypersensitivity to Chinese hamster ovarian
             (CHO) cell products or any component of the Atezolizumab formulation. Patients with a
             known allergy to either of the drugs individually

          3. Use of any standard or experimental anti-cancer drug therapy within 4 weeks prior to
             the first scheduled treatment dose (C1D1).

          4. History of treatment with anti-PD1 or anti-PDL1.

          5. Significant immunosuppression from:

               -  Concurrent, recent (≤ 2 weeks ago) or anticipated treatment with systemic
                  corticosteroids at dose &gt;10mg/day of prednisolone (or equivalent)

               -  Other immunosuppressive medications such as methotrexate, cyclosporine,
                  azathioprine

               -  Any immunosuppressive condition such as common variable hypogammaglobulinemia

          6. Myocardial infarction within 6 months prior to first study drug, active cardiac
             ischemia or New York Heart Association (NYHA) Grade III or IV heart failure, severe
             arrhythmia, unstable arrhythmias, or unstable angina) or pulmonary disease (including
             uncontrolled obstructive pulmonary disease and history of bronchospasm or other
             according to investigator's decision)

          7. left ventricular ejection fraction (LVEF) &lt; 45% as determined by echocardiography or
             multiple uptake gated acquisition (MUGA) scan

          8. Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          9. Prior history of other cancer other than lymphoma within 2 years (except basal cell
             carcinoma, in situ squamous and non-squamous cell carcinomas completely resected (R0)
             and prostate cancers with normal results for more than 6 months)

         10. Recent (&lt; 1 month ago) clinically significant infection, active tuberculosis or
             antibiotics therapy

         11. Central nervous system involvement with lymphoma, including parenchymal and
             leptomeningeal disease. Patients with asymptomatic focal epiduritis on imaging might
             be included with the Sponsor's approval.

         12. Ongoing or history of autoimmune disease, including active non-infectious pneumonitis,
             with the exception of alopecia, vitiligo, auto-immune endocrine deficiency with stable
             hormone replacement therapy, controlled skin eczema and stable asymptomatic and
             treated asthma. Patients with severe auto-immune disease in one of their parents,
             siblings, or children will not be eligible.

         13. Psychiatric, other medical illness or other condition that in the opinion of the PI
             prevents compliance with study procedures or ability to provide valid informed consent

         14. Use of anti-coagulant agents or history a significant bleeding diathesis. If a
             superficial lymph node or subcutaneous mass is to be injected, patients on agents such
             as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are
             eligible and these agents do not have to be withheld. For procedures with moderate or
             significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should
             be discussed with the Sponsor and may need to be discontinued before Selicrelumab
             therapy. Patients under preventive dose of low molecular weight heparin (LMWH) are
             eligible if they can stop their treatment 24h prior the IT injection and restart 24h
             after the injection. No anticoagulant restriction for patients with injected lesions
             being superficial tumor lesions eligible for at least 5mn mechanical compression after
             tumor biopsy &amp; injections (as in routine interventional radiology practice).

         15. Subcapsular liver tumor lesions of tumor encased vessels or not eligible for
             intratumoral biopsies or injections.

         16. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study
             treatment, or anticipation of need for such a vaccine during Atezolizumab treatment or
             within 5 months after the last dose of Atezolizumab

         17. Prior allogeneic hematopoietic stem cell transplantation

         18. Patients who have undergone a solid organ transplant

         19. Documented infection with HIV

         20. Positive serology to hepatitis B. Patients with previous and cured infections are not
             eligible. Patients who are seropositive due to a history of hepatitis B vaccine are
             eligible.

         21. History or presence of an abnormal ECG that is clinically significant in the
             investigator's opinion, including complete left bundle branch block, second- or third
             degree heart block, or evidence of prior myocardial infarction

         22. Person deprived of his/her liberty by a judicial or administrative decision

         23. Person hospitalized without consent

         24. Adult person under legal protection

         25. Adult person unable to provide informed consent because of intellectual impairment,
             any serious medical condition, laboratory abnormality or psychiatric illness

         26. Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roch HOUOT, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ombeline Vérité</last_name>
    <phone>+33 (0)4 72 66 93 33</phone>
    <email>verite.ombeline@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>APHP - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François LEMONNIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Cartron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bachy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roch Houot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien Marabelle</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

